- Home
- LLYVA vs LEGN Comparison
LLYVA vs LEGN Comparison
Compare LLYVA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- LEGN
- Stock Information
- Founded
- LLYVA 1991
- LEGN 2014
- Country
- LLYVA United States
- LEGN United States
- Employees
- LLYVA N/A
- LEGN N/A
- Industry
- LLYVA Broadcasting
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVA Industrials
- LEGN Health Care
- Exchange
- LLYVA Nasdaq
- LEGN Nasdaq
- Market Cap
- LLYVA 6.0B
- LEGN 7.0B
- IPO Year
- LLYVA N/A
- LEGN 2020
- Fundamental
- Price
- LLYVA $67.53
- LEGN $32.80
- Analyst Decision
- LLYVA
- LEGN Strong Buy
- Analyst Count
- LLYVA 0
- LEGN 12
- Target Price
- LLYVA N/A
- LEGN $79.00
- AVG Volume (30 Days)
- LLYVA 211.7K
- LEGN 1.6M
- Earning Date
- LLYVA 01-01-0001
- LEGN 05-12-2025
- Dividend Yield
- LLYVA N/A
- LEGN N/A
- EPS Growth
- LLYVA N/A
- LEGN N/A
- EPS
- LLYVA N/A
- LEGN N/A
- Revenue
- LLYVA N/A
- LEGN $627,241,000.00
- Revenue This Year
- LLYVA $7.29
- LEGN $66.92
- Revenue Next Year
- LLYVA N/A
- LEGN $51.77
- P/E Ratio
- LLYVA N/A
- LEGN N/A
- Revenue Growth
- LLYVA N/A
- LEGN 119.97
- 52 Week Low
- LLYVA $32.55
- LEGN $29.27
- 52 Week High
- LLYVA $79.63
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- LLYVA 51.40
- LEGN 45.92
- Support Level
- LLYVA $64.92
- LEGN $29.27
- Resistance Level
- LLYVA $67.99
- LEGN $35.11
- Average True Range (ATR)
- LLYVA 3.53
- LEGN 1.89
- MACD
- LLYVA 0.30
- LEGN 0.16
- Stochastic Oscillator
- LLYVA 67.35
- LEGN 60.48
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.